Jagsonpal Pharma’s shares rose 0.77% to ₹227.65 on the BSE after the company disclosed a ₹46.7 crore acquisition of Group Pharma’s wellness portfolio. The BSE filing notes the deal is a slump sale, with an initial ₹23.7 crore payment on closing and an additional upside of up to ₹23 crore tied to FY27‑28 sales, subject to a cap at ₹46.7 crore.
The wellness portfolio recorded ₹24.6 crore in turnover for FY25‑26, covering identified products, contracts and employees across India. By integrating the portfolio into its existing commercial platform, Jagsonpal plans to leverage its 1,000‑strong field force and pan‑India distribution network to generate operating synergies.
According to Managing Director Manish Gupta, the acquisition strengthens Jagsonpal’s focus on women’s healthcare, orthopaedics and dermatology—its core therapeutic segments. COO Amrut Medhekar added that the transition will be seamless, with employees and operations expected to dovetail into Jagsonpal’s infrastructure.
The transaction does not trigger related‑party rules, and no regulatory approvals are required. Closing is expected on or before Nov 1, 2026, once all conditions precedent are satisfied.
Jagsonpal’s previous move to acquire an 85% stake in Aequitas Healthcare for ₹21 crore highlights a consistent asset‑light growth strategy, aiming to expand market reach without heavy capital outlay. Investors will be watching the integration for potential cross‑selling and margin expansion.
With the deal’s completion, Jagsonpal could broaden its product pipeline and reinforce its presence in key therapeutic areas, potentially lifting future earnings and share valuation.